Revisiting the Real Impact
An oncologist’s opinion on the value of fully automated NGS results in a single day
sponsored by Thermo Fisher Scientific
After its launch in Baltimore at the Association for Molecular Pathology (AMP)’s 2019 annual meeting, the Ion TorrentTM GenexusTM System from Thermo Fisher Scientific is catalyzing conversations in the precision medicine community. The system features a unique automated specimen-to-report workflow that delivers results economically in a single day and, in my opinion, holds unprecedented potential to advance precision medicine. Its unmatched turnaround time – as little as 14 hours to final results – is extremely appealing for clinician-scientists who are confronted with the need to make decisions fast.
To learn more about the new system’s advantages from an oncologist’s point of view, Luca Quagliata, Global Head of Medical Affairs at Thermo Fisher Scientific, sat down with Elena Garralda, Principal Investigator at the Vall d’Hebron Institute of Oncology (VHIO) Early Clinical Drug Development Group and Director of the Research Unit for Molecular Therapy of Cancer (UITM) “la Caixa.” Garralda shares her thoughts on the benefits of obtaining a complete molecular profile of a tumor sample within a single day – both for clinical research and, in the future, for routine management of cancer patients.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine